BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis

Company Overview

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here. Prospective investors and researchers should consult the company’s SEC filings, investor presentations and official disclosures for up-to-date details on its pipeline, management team and strategic priorities.

Key Stats

• Today's Range: $8.15 to $8.67
• 50-Day Range: $8.06 to $10.42
• 52-Week Range: $8.00 to $14.87
• Volume: 173,573 shs
• Average Volume: 329,919 shs
• Market Capitalization: $662.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.00
• Consensus Rating: Moderate Buy

BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™

BridgeBio Oncology Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 46th out of 69 stocks in the financial services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

BridgeBio Oncology Therapeutics has a consensus price target of $26.00, representing about 214.4% upside from its current price of $8.27.

Amount of Analyst Coverage

BridgeBio Oncology Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BridgeBio Oncology Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BridgeBio Oncology Therapeutics is -5.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BridgeBio Oncology Therapeutics is -5.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BridgeBio Oncology Therapeutics has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BBOT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BridgeBio Oncology Therapeutics does not currently pay a dividend.

Dividend Growth

BridgeBio Oncology Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: -0.49

News Sentiment

BridgeBio Oncology Therapeutics has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Financial Services companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BBOT Stock Analysis - Frequently Asked Questions

How have BBOT shares performed this year?

BridgeBio Oncology Therapeutics' stock was trading at $11.50 at the beginning of 2026. Since then, BBOT stock has decreased by 28.1% and is now trading at $8.27.

How do I buy shares of BridgeBio Oncology Therapeutics?

Shares of BBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Financial Services
• Industry: Investment Offices
• Sub-Industry: Trading
• Current Symbol: NASDAQ:BBOT
• CIK: 1869105
• Web: bbotx.com
• Phone: (857) 702-0377
• Fax: N/A
• Employees: N/A
• Year Founded: 2025

Price Target and Rating

• Average Price Target for BridgeBio Oncology Therapeutics: $26.00
• High Price Target: $29.00
• Low Price Target: $23.00
• Potential Upside/Downside: +214.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.34
• Quick Ratio: 12.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.14 per share
• Price / Book: 1.61

Miscellaneous

• Outstanding Shares: 80,110,000
• Free Float: N/A
• Market Cap: $662.51 million
• Optionable: N/A
• Beta: 0.22